In a published note, Wedbush reiterates its Neutral rating and $34 target price on BioMarin Pharmaceutical Inc. BMRN as the company announces GALNS 2 trial testing initiation.
Wedbush comments, “GALNS gross peak annual sales potential could reach $600-900 million. With successful clinical development and regulatory approval, we anticipate launch could occur in 2013. The company has already identified over 900 MPS-IV patients and there are about 3,000 patients estimated worldwide.”
BMRN closed at $33.42 per share on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in